Company intelligence / Profile preview

EveryONE Medicines

Boston, Massachusetts, United Stateseveryonemedicines.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EveryONE Medicines is pioneering a system to deliver individualized antisense oligonucleotide therapies tailored to the unique genetic mutations of children with life-threatening neurodegenerative diseases. Inspired by the first n-of-one drug "milasen," the company aims to make such personalized treatments routine and accessible at scale. The company is building a proprietary AI-enabled platform and an expanding library of ASOs, but has not yet reported clinical trial results or commercialized products

Therapeutic areas: Neurology
Modalities: Antisense oligonucleotides (ASOs)Nucleic acid therapeutics
Industry: Biotech

Drug pipeline

1 asset

individualized antisense oligonucleotide

Beyond the preview

Go deeper on EveryONE Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EveryONE Medicines.

Explore the full profile